Johnson & Johnson (JNJ) announced that it has submitted a supplemental biologics license application (sBLA) seeking approval of its immunology drug, Tremfya, for a new indication — moderately to severely active Crohn’s disease (CD). This marks the second label expansion filing for Tremfya in three months, following the sBLA in active ulcerative colitis (UC) indication that was filed in March. Tremfya is currently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in seve ...